Brocair advises Biomain AB in sale to Heraeus Group

Brocair Partners LLC, an investment bank serving the healthcare industry, advised Biomain AB in its sale to Heraeus Group

NEW YORK, NY – March 5, 2012 – Brocair Partners LLC, an investment banking firm serving the healthcare industry, in conjunction with Experia Corporate Finance Advisors AB, based in Stockholm, advised Biomain AB, a Helsingborg, Sweden-based dental prosthetics company, on their sale to Heraeus Dental, part of the Heraeus Group, a precious metals and technology holding company based in Hanau, Germany.

The acquisition strengthens Heraeus’ presence in the Northern European dental market and expands its patent and product portfolio in digital implant prosthetics.

Gregg Blake, Managing Partner of Brocair, explained, “Biomain had a set of products and intellectual property that had enabled them to attain a dominant position in the Nordics in the CAD/CAM dental prosthetics space. This is a rapidly growing market, and we found there was strong demand from major dental industry players with a strategic interest in the field. The valuation reflected the competitive nature of the process and the high level of strategic interest.”

Anders Williamsson, Chairman of Biomain, remarked “As Chairman of the business, I was impressed with the speed and quality of the investment banking effort, and the transaction value was an exceptional endorsement of the quality of the business. The Board and owners were extremely pleased with the whole process, and the outcome was a classic win-win situation for both the company and the buyer.”

Håkan Persson, Managing Partner of Experia, commented “This demonstrates again the virtues of a transatlantic advisory team with members from both Brocair and Experia. With professionals covering our different geographies and time zones, we could market the opportunity to all relevant parties, creating the competitive selling process that was the key to the successful outcome for our client.”

Mr. Blake summarized, “The transaction was an excellent fit for both parties—Biomain has the advantage of being part of a larger platform, and Heraeus has an opportunity to expand its product range and market share in Northern Europe.”

The purchase price was not disclosed, but Swedish press reports indicate the valuation was in excess of SEK 200 million.

Founded in 2002, Biomain AB, based in Helsingborg, Sweden, is the Scandinavian market leader in the field of custom CAD/CAM-produced implant prosthetics and has a workforce of 40 employees.

Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Its fields of competence include precious metals, materials and technologies; sensors; biomaterials; and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metals trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.